MA54521A - Dérivés d'oxopyridine substitués - Google Patents
Dérivés d'oxopyridine substituésInfo
- Publication number
- MA54521A MA54521A MA054521A MA54521A MA54521A MA 54521 A MA54521 A MA 54521A MA 054521 A MA054521 A MA 054521A MA 54521 A MA54521 A MA 54521A MA 54521 A MA54521 A MA 54521A
- Authority
- MA
- Morocco
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- oxopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54521A true MA54521A (fr) | 2022-03-30 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054521A MA54521A (fr) | 2018-12-21 | 2019-12-18 | Dérivés d'oxopyridine substitués |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (es) |
| JP (1) | JP2022514303A (es) |
| KR (1) | KR20210106504A (es) |
| CN (1) | CN113474348A (es) |
| AR (1) | AR117435A1 (es) |
| AU (1) | AU2019407909B2 (es) |
| BR (1) | BR112021009435A2 (es) |
| CA (1) | CA3124220A1 (es) |
| CL (1) | CL2021001613A1 (es) |
| CO (1) | CO2021007908A2 (es) |
| CR (1) | CR20210342A (es) |
| DO (1) | DOP2021000128A (es) |
| EA (1) | EA202191764A1 (es) |
| EC (1) | ECSP21043895A (es) |
| IL (1) | IL283990A (es) |
| JO (1) | JOP20210161A1 (es) |
| MA (1) | MA54521A (es) |
| MX (1) | MX2021007508A (es) |
| PE (1) | PE20211790A1 (es) |
| SG (1) | SG11202104384PA (es) |
| TW (1) | TW202039510A (es) |
| WO (1) | WO2020127504A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111770917B (zh) * | 2018-03-15 | 2023-09-26 | 拜耳股份公司 | 两种化合物的制备方法 |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| MX2023010629A (es) | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida. |
| BR112023016298A2 (pt) | 2021-03-09 | 2023-10-03 | Bayer Ag | Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| EP3024822B1 (de) | 2013-07-23 | 2017-05-03 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate und ihre verwendung als faktor xia und plasmakallikrein inhibitoren |
| JP6368367B2 (ja) | 2013-10-30 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
| ES2722423T3 (es) * | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| ES2712886T3 (es) * | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| ES2713624T3 (es) | 2014-09-24 | 2019-05-23 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| EP3197872B1 (de) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen |
| ES2694189T3 (es) | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| EP3197880B1 (de) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung |
| CN107428689A (zh) * | 2015-03-19 | 2017-12-01 | 拜耳制药股份公司 | 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物 |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| WO2017037051A1 (de) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019407909B2 (en) | 2023-05-25 |
| CO2021007908A2 (es) | 2021-07-19 |
| IL283990A (en) | 2021-07-29 |
| DOP2021000128A (es) | 2021-09-30 |
| TW202039510A (zh) | 2020-11-01 |
| KR20210106504A (ko) | 2021-08-30 |
| EA202191764A1 (ru) | 2021-10-22 |
| ECSP21043895A (es) | 2021-07-30 |
| CR20210342A (es) | 2021-08-09 |
| PE20211790A1 (es) | 2021-09-09 |
| JOP20210161A1 (ar) | 2023-01-30 |
| CA3124220A1 (en) | 2020-06-25 |
| AU2019407909A1 (en) | 2021-05-27 |
| SG11202104384PA (en) | 2021-05-28 |
| BR112021009435A2 (pt) | 2021-08-17 |
| CL2021001613A1 (es) | 2021-12-03 |
| JP2022514303A (ja) | 2022-02-10 |
| AR117435A1 (es) | 2021-08-04 |
| WO2020127504A1 (en) | 2020-06-25 |
| EP3898633A1 (en) | 2021-10-27 |
| CN113474348A (zh) | 2021-10-01 |
| MX2021007508A (es) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| MA52948A (fr) | Composés | |
| MA51669A (fr) | Composés | |
| DK3794042T3 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA49127A (fr) | Dérivés d'indole n-substitués | |
| MA53003A (fr) | Composés | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| DK3870578T3 (da) | Terapeutiske forbindelser | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| MA52946A (fr) | Composés | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA52934A (fr) | Composés inhibiteurs de l'oga | |
| MA52937A (fr) | Composés inhibiteurs d'oga | |
| MA52936A (fr) | Composés inhibiteurs d'oga | |
| MA56504A (fr) | Dérivés de pyridin-3-yle | |
| DK3894410T3 (da) | Substituerede xanthinderivater |